By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Quark Pharmaceuticals Inc. 

6501 Dumbarton Circle

Fremont  California  94555  U.S.A.
Phone: 510-402-4020 Fax: 510-402-4021


SEARCH JOBS








Company News
Quark Pharmaceuticals Inc. To Present Keynote Address At IBC's 18th Annual TIDES Oligonucleotide And Peptide Therapeutics Conference 5/9/2016 9:12:46 AM
Transplant Genomics And Quark Pharmaceuticals Inc. Announce Discovery And Development Collaboration 4/14/2016 6:25:07 AM
Quark Pharmaceuticals Inc. Doses First Patients In Two Pivotal Phase III Studies And One Phase II Study Of RNAi-Based Therapeutics For Kidney And Eye Indications 3/14/2016 6:18:57 AM
Quark Pharmaceuticals Inc. Announces Initiation Of Patient Recruitment For Global Pivotal Study Of QPI-1007 In NAION 10/27/2015 7:40:51 AM
Quark Pharmaceuticals Inc. Reports Favorable Data From Phase 2 Clinical Trial Evaluating Investigational siRNA QPI-1002 7/29/2014 6:31:05 AM
Quark Pharmaceuticals Inc. Reports Favorable Results From Phase 2 Clinical Trial Evaluating Investigational Sirna QPI-1002 7/28/2014 10:34:03 AM
Quark Pharmaceuticals Inc. Announces Completion Of Phase 2 Trial Evaluating QPI-1002 For Prevention Of Delayed Graft Function In Kidney Transplant Patients 7/1/2014 9:02:30 AM
Quark Pharmaceuticals Inc. Announces First Patient Dosed In A Phase 2a Trial Evaluating QPI-1007 For Neuroprotection In Patients With Acute Primary Angle Closure Glaucoma 6/25/2014 9:15:28 AM
Quark Pharmaceuticals Inc. And Suzhou Ribo Life Science Raise Nearly RMB 45 Million For Newly Established Chinese Joint Venture 1/7/2014 9:33:17 AM
Silence Therapeutics plc' Partner, Quark Pharmaceuticals Inc., Extends its Agreement With Pfizer Inc. (PFE) to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 5/3/2012 7:02:19 AM
123456
//-->